Feedback (AIM:FDBK) reported flat revenue of approximately £0.8m for the year ended 31 May, against £0.9m in the prior year, in an unaudited trading update.
The AIM-listed clinical infrastructure specialist said its EBITDA loss for the period would come in lower than both market expectations and the previous year's figure, helped by cost controls and cash management.
Cash balances stood at £2.7m at year-end, ahead of expectations on faster collections and cost discipline, giving the company a runway through to mid-2027.
Feedback said it continues to pursue a potential national contract with NHS England for its Bleepa clinical pathway technology, building on its pilot at Queen Victoria Hospital (QVH) in Sussex, and said it is hopeful of a decision around the calendar year-end once NHS England and HM Treasury conclude their evaluation.
During the period, the company integrated Bleepa with the NHS e-Referral Service, which it said drove a tenfold increase in GP practices referring into the platform within weeks, alongside integrations with Patients Know Best and QVH's Evolve electronic medical record system.
Feedback also released version 1.7 of Bleepa, adding data reporting, security and automation features aimed at cutting NHS customers' operating costs.
"There are grounds for optimism," said Dr Tom Oakley, chief executive, pointing to a "growing recognition of Bleepa at all levels of the NHS" as commissioning bodies consolidate.
The company said England's Referral to Treatment waiting list has fallen only 7% in the 31 months since peaking at 7.77m in September 2023.
